Looking back, glaucoma specialists like Dr. Christine Funke of Barnet Dulaney Perkins Eye Center can remember a time not long ago when treatment options for the eye condition were greatly limited.

Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma ...

AND JESS, YOU SAY THIS COULD BE A GAME CHANGER. YOU KNOW, IT REALLY CAN. ABOUT 3 MILLION AMERICANS HAVE GLAUCOMA AND THIS NEW TREATMENT IS BASICALLY AN IMPLANTABLE DRUG FOR THE EYE. AND DOCTORS SAY IT ...

Shared insight on how the use and sequencing of therapies for glaucoma will evolve in coming years. Neil Minkoff, MD: Where do we see glaucoma therapy going in the next 24 to 36 months, due to ...

Please provide your email address to receive an email when new articles are posted on . Glaucoma-related ocular surface disease is a significant and often underdiagnosed ocular comorbidity that can ...

USA: A large retrospective cohort study found that the dual GIP/GLP-1 receptor agonist tirzepatide was associated with a ...

Glaucoma causes vision loss by damaging the optic nerve. This leads to loss of peripheral vision and eventually blindness. The damage to the optic nerve is multifactorial, but increased ocular ...

The CDC reports that over three million Americans have glaucoma. The number may reach 6.3 million by 2050 as the aging population grows. Glaucoma is affecting so many lives, so it’s important to know ...

We found the following factors were important for predicting the progression of glaucoma: (1) the presence of small bleeding and poor blood flow to the retina and back of the eye, (2) abnormal cell ...

In a survey, nearly two-thirds of patients with glaucoma or ocular hypertension were unaware of preservative-free topical ...